NCT06290557 (HY-133) is a Phase 1 clinical trial of HY_133 in Staphylococcus Aureus, sponsored by University Hospital Tuebingen.

Who is sponsoring NCT06290557?

NCT06290557 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT06290557?

Interventions in NCT06290557: HY_133, Placebo.

What condition does NCT06290557 study?

NCT06290557 studies Staphylococcus Aureus.

Is NCT06290557 still recruiting?

NCT06290557 is currently recruiting now. Last updated 6 December 2024.

Last reviewed 2024-12-06 · How we verify

NCT06290557: HY-133

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133

Recruiting now Phase 1 Last updated 6 December 2024

What this trial tests

Phase 1 trial testing HY_133 in Staphylococcus Aureus in 52 participants. Currently enrolling.

Timeline

10 July 2024

Primary endpoint
1 July 2025

1 July 2026

Quick facts

Lead sponsor	University Hospital Tuebingen
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	52
Start date	10 July 2024
Primary completion	1 July 2025
Estimated completion	1 July 2026
Sites	2 locations across Germany

Drugs / interventions tested

HY_133 — full drug profile →
Placebo

Conditions studied

Staphylococcus Aureus — all drugs for Staphylococcus Aureus →

Sponsor

University Hospital Tuebingen

Who can join

18 and older, any sex, with Staphylococcus Aureus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this clinical trial we will test a new approach for decolonization of S. aureus. As innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy subjects once or five times in one day. To avoid possible bias the subjects will be randomized 3:2 verum vs placebo, moreover the subject as well as the investigator will be blinded to the group assigned.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.
Taati Moghadam M, Mohebi S, Sheikhi R, Hasannejad-Bibalan M, et al · · 2025 · cited 4× · PMID 40661138 · DOI 10.1002/mco2.70280
Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review.
Vander Elst N. · · 2026 · cited 1× · PMID 41514460 · DOI 10.1186/s40001-025-03655-4
Limitation of the Lytic Effect of Bacteriophages on <i>Salmonella</i> and Other Enteric Bacterial Pathogens and Approaches to Overcome.
Tung CW, Julianingsih D, Phan A, Canagarajah C, et al · · 2025 · cited 1× · PMID 40405891 · DOI 10.1155/ijm/5936070
[Phage endolysins-a novel class of antibacterial agents with a wide range of applications].
Idelevich EA, Becker K. · · 2025 · PMID 40328935 · DOI 10.1007/s00103-025-04059-9

Verify or expand the search:

Other recruiting trials for Staphylococcus Aureus

Currently open trials in the same condition.

NCT06633588 — Decolonization Efficacy of Polyhexanide vs. Mupirocin · Phase 4 · recruiting
NCT06749457 — A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Dis · Phase 1, PHASE2 · recruiting
NCT06283355 — Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome · Phase 1 · recruiting
NCT05695196 — Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant · Phase 1 · active not recruiting
NCT05094570 — Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP · Phase 4 · recruiting

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06290557 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 6 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06290557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing